Based on the Akoya Biosciences Inc stock forecast from 4 analysts, the average analyst target price for Akoya Biosciences Inc is USD 2.99 over the next 12 months. Akoya Biosciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Akoya Biosciences Inc is Bearish, which is based on 2 positive signals and 8 negative signals. At the last closing, Akoya Biosciences Inc’s stock price was USD 1.16. Akoya Biosciences Inc’s stock price has changed by -7.20% over the past week, -6.45% over the past month and -72.80% over the last year.
No recent analyst target price found for Akoya Biosciences Inc
No recent average analyst rating found for Akoya Biosciences Inc
Company Overview Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Read Less
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a com...Read More
Frequently Asked Questions About Akoya Biosciences Inc (AKYA) Stock
Based on ratings from 4 analysts Akoya Biosciences Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AKYA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for AKYA is USD 2.99 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 1.65.
Unfortunately we do not have enough data on AKYA's stock to indicate if its overvalued.
The last closing price of AKYA's stock was USD 1.16.
The most recent market capitalization for AKYA is USD 0.05B.
Based on targets from 4 analysts, the average taret price for AKYA is projected at USD 2.99 over the next 12 months.
This means that AKYA's stock price may go up by +157.76% over the next 12 months.
We can't find any ETFs which contains Akoya Biosciences Inc's stock.
As per our most recent records Akoya Biosciences Inc has 205 Employees.
Akoya Biosciences Inc's registered address is 100 Campus Drive, Marlborough, MA, United States, 01752.
You can get more information about it from Akoya Biosciences Inc's website at https://www.akoyabio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Akoya Biosciences Inc (AKYA) Stock
Based on ratings from 4 analysts Akoya Biosciences Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AKYA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for AKYA is USD 2.99 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 1.65.
Unfortunately we do not have enough data on AKYA's stock to indicate if its overvalued.
The last closing price of AKYA's stock was USD 1.16.
The most recent market capitalization for AKYA is USD 0.05B.
Based on targets from 4 analysts, the average taret price for AKYA is projected at USD 2.99 over the next 12 months.
This means that AKYA's stock price may go up by +157.76% over the next 12 months.
We can't find any ETFs which contains Akoya Biosciences Inc's stock.
As per our most recent records Akoya Biosciences Inc has 205 Employees.
Akoya Biosciences Inc's registered address is 100 Campus Drive, Marlborough, MA, United States, 01752.
You can get more information about it from Akoya Biosciences Inc's website at https://www.akoyabio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AKYA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
